Methodology and Early Results of the First Surveillance Program on Prevention and Control of Antimicrobial Resistance in Isfahan, Iran: The IAS-I Study
Abstract
Background: Isfahan Antibiotic Resistance Surveillance System‑1 has been instituted in Isfahan, Iran to construct a project for surveillance of clinically significant bacteria, and to help raise a logic regional stewardship program for prevention and control of disseminating‑resistant organisms.
Methods: During March 2016 to March 2018, an antibiotic resistance surveillance system was designed and implemented by Isfahan Infectious Diseases and Tropical Medicine Research Center. The surveillance program was implemented in three general hospitals in Isfahan. In addition to the routine microbiology data, clinical data (differentiation between true infections and contamination, healthcare‑associated infections (HCAI) and community‑acquired infections (CAI), as well as determination of the infection site) were obtained and analyzed by WHONET software.
Results: During a 2‑year period, from 7056 samples that revealed growth of bacteria, 3632 (51.5%) isolates were detected as contamination and 3424 (48.5%) true bacterial isolates were identified. Of these, about 32% of isolates were recognized as HCAI. Totally, the most recognized infections were urinary tract infection, bloodstream infection and skin and soft tissue infections. In patients with HCAIs, 70% of isolates were gram negative and in patients with CAIs 73% isolates were gram negative bacteria.
Conclusions: The strength of the project is gathering enough clinical information in addition to microbiologic data, which would increase application of the results for empiric treatment and prevention of the infectious diseases in clinical settings.
Keywords
Full Text:
PDFReferences
World Health Organization. Antimicrobial Resistance: Global
Report on Surveillance. WHO; 2014.
Vernet G, Mary C, Altmann DM, Doumbo O, Morpeth S,
Bhutta ZA, et al. Surveillance for antimicrobial drug resistance
in under‑resourced countries. Emerg Infect Dis 2014;20:434‑41.
Ashley E, Recht J, Chua A. Antimicrobial Resistance in Low
and Middle Income Countries: An analysis of Surveillance
Network. Report 2017. Available from: https://www.iddo.
org/external‑publication/antimicrobial‑resistance‑low‑
and‑middle‑income‑countries‑analysis‑surveillance.[Last
Cited on 2018 Nov 11].
Dadashi M, Nasiri MJ, Fallah F, Owlia P, Hajikhani B,
Emaneini M, et al. Methicillin‑resistant Staphylococcus aureus
(MRSA) in Iran: A systematic review and meta‑analysis. J Glob
Antimicrob Resist 2018;12:96‑103.
Alizade H. Escherichia coli in Iran: An overview of antibiotic
resistance: A review article. Iran J Public Health 2018;47:1‑12.
Heidary M, Nasiri MJ, Dabiri H, Tarashi S. Prevalence of
drug‑resistant Klebsiella pneumoniae in Iran: A review article.
Iran J Public Health 2018;47:317‑26.
Emaneini M, Hosseinkhani F, Jabalameli F, Nasiri MJ,
Dadashi M, Pouriran R, et al. Prevalence of vancomycin‑resistant
enterococcus in Iran: A systematic review and meta‑analysis. Eur
J Clin Microbiol Infect Dis 2016;35:1387‑92.
Mostafavi N, Bighamian M, Mobasherizade S, Kelishadi R.
Resistance of Shigella strains to extended‑spectrum
cephalosporins in Isfahan province. Med J Islam Repub Iran
;30:428.
Khademi F, Poursina F, Hosseini E, Akbari M, Safaei HG.
Helicobacter pylori in Iran: A systematic review on the antibiotic
resistance. Iran J Basic Med Sci 2015;18:2‑7.
Karimian M, Kermani R, Khaleghi M, Kelishadi R, Ataei B,
Mostafavi N. Antibiotic susceptibility patterns of isolates
from children with urinary tract infection in Isfahan, Iran:
Impact on empirical treatment. J Glob Antimicrob Resist
;9:3‑7.
Farid GA, Moghaddam AB, Bojdy A. Nosocomial pneumonia
in patients admitted to the intensive care unit of a tertiary care
center in Mashhad, Northeast of Iran; An Etiologic Survey. Arch
Clin Infect Dis 2018;13:e64239.
World Health Organization. Global Antimicrobial Resistance
Surveillance System: Manual for Early Implementation. WHO;
Clinical and Laboratory Standards Institute. Performance
standards for antimicrobial susceptibility testing;
nd informational supplement. 2015, CLSI M100‑S25.
Hall KK, Lyman JA. Updated review of blood culture
contamination. Clin Microbiol Rev 2006;19:788‑802.
Lee CC, Lin WJ, Shih HI, Wu CJ, Chen PL, Lee HC, et al.
Clinical significance of potential contaminants in blood cultures
among patients in a medical center. J Microbiol Immunol Infect
;40:438‑44.
Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance
definition of health care‑associated infection and criteria for
specific types of infections in the acute care setting. Am J Infect
Control 2008;36:309‑32.
Monnet DL. Toward multinational antimicrobial resistance
surveillance systems in Europe. Int J Antimicrob Agents
;15:91‑101.
Bax R, Bywater R, Cornaglia G, Goossens H, Hunter P, Isham V,
et al. Surveillance of antimicrobial resistance—what, how and
whither? Clin Microbiol Infect 2001;7:316‑25.
Fluit AC, Schmitz FJ, Jones ME, Acar J, Gupta R, Verhoef J.
The SENTRY participants group. Antimicrobial resistance among
community‑acquired pneumonia isolates in Europe: First results
from the SENTRY antimicrobial surveillance program 1997. Int
J Infect Dis 1999;3:153‑6.